Paul Rubin

Paul Rubin

Paul Rubin is a corporate partner based in the Washington, D.C. office and a member of Debevoise and Plimpton’s Healthcare Group. He is noted as a recognized practitioner for Regulatory Healthcare by Chambers USA (2018) and is an LMG Life Sciences: “Life Sciences Star” (2013–2018). Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues, ranging from strategic regulatory counseling to complex compliance and enforcement matters. He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions. In addition to his FDA practice, Mr. Rubin also has substantial experience helping clients navigate complex advertising and promotion-related issues, including FTC investigations, negotiating FTC settlements/consent decrees, disputes before the National Advertising Division of the Better Business Bureau (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act.

For more information or to contact Mr. Rubin, please visit his Firm Profile Page.


Posts by Paul Rubin


Rule Requiring Prescription Drug Price Disclosures in TV Ads Will Create Complex Lanham Act Enforcement Issues and First Amendment Implications

A Final Rule issued by the Centers for Medicare and Medicaid Services (CMS) on May 8 (the “Final Rule”) that requires direct-to-consumer (DTC) television advertisements for a prescription …